Xu-Dong Feng, MD, PhD, Doctor, Department of Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, Affiliated Lihuili Hospital of Ningbo University, No. 57 Xingning Road, Ningbo 315000, Zhejiang Province, China. xdfeng@zju.edu.cn
Research Domain of This Article
Cell & Tissue Engineering
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Sep 26, 2024; 16(9): 846-853 Published online Sep 26, 2024. doi: 10.4252/wjsc.v16.i9.846
Innovative mesenchymal stem cell treatments for fatty liver disease
Fei-Qiong Gao, Jia-Qi Zhu, Xu-Dong Feng
Fei-Qiong Gao, Department of Endocrinology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou 310003, Zhejiang Province, China
Jia-Qi Zhu, Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
Xu-Dong Feng, Department of Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, Affiliated Lihuili Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China
Co-first authors: Fei-Qiong Gao and Jia-Qi Zhu.
Author contributions: Gao FQ and Zhu JQ made equal contributions to this study. Gao FQ and Zhu JQ prepared and wrote the manuscript; Feng XD wrote and revised the manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu-Dong Feng, MD, PhD, Doctor, Department of Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, Affiliated Lihuili Hospital of Ningbo University, No. 57 Xingning Road, Ningbo 315000, Zhejiang Province, China. xdfeng@zju.edu.cn
Received: July 22, 2024 Revised: August 26, 2024 Accepted: September 9, 2024 Published online: September 26, 2024 Processing time: 63 Days and 22.1 Hours
Core Tip
Core Tip: Mesenchymal stem cells (MSCs) and their derivatives are a promising therapeutic approach for non-alcoholic fatty liver disease and alcohol-associated liver disease. MSCs, which come from diverse sources and are of low immunogenicity, can attenuate disease progression by modulating key molecular pathways, such as glycolipid metabolism, inflammation, oxidative stress, and fibrosis. In addition, derivatives of MSCs are also considered as a therapeutic strategy due to their ability to retain some of the beneficial effects of MSCs while reducing the risks inherent in cell therapy. However, further studies are needed to emphasize their important mechanistic role in liver injury repair. Refining protocols for the clinical application of MSCs under the prerequisite of a well-defined mechanistic understanding may allow utilizing the full benefits of MSCs in the treatment of liver disease to enhance liver reparability and provide new hope for the treatment of non-alcoholic fatty liver disease and alcohol-associated liver disease.
